Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 12/20 | 0.49 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 3/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.40 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.38 |
| ▸ | KCNK5 | O95279 | 1/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.38 |
| ▸ | KCNK17 | Q96T54 | 1/20 | 0.38 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL755280 | 0.90 | BDKRB1 (0.43) | BDKRB1F10CNR1CHRM4KCNK3 | |
| SCHEMBL765812 | 0.86 | BDKRB1 (0.63) | BDKRB1F10EPHX2 | |
| SCHEMBL12239079 | 0.85 | BDKRB1 (0.44) | BDKRB1CNR1 | |
| SCHEMBL2547691 | 0.84 | BDKRB1 (0.53) | BDKRB1F10CNR1CHRM4 | |
| SCHEMBL12262806 | 0.84 | BDKRB1 (0.55) | BDKRB1F10CNR1 | |
| SCHEMBL2546946 | 0.84 | BDKRB1 (0.47) | BDKRB1CNR1 | |
| SCHEMBL764471 | 0.84 | BDKRB1 (0.43) | BDKRB1CNR1 | |
| SCHEMBL12239080 | 0.82 | BDKRB1 (0.45) | BDKRB1F10 | |
| SCHEMBL765664 | 0.81 | CNR1 (0.56) | BDKRB1CNR1 | |
| SCHEMBL4986828 | 0.81 | BDKRB1 (0.48) | BDKRB1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150011513-A1 | ALKYNE-, AZIDE- AND TRIAZOLE-CONTAINING FLAVONOIDS AS MODULATORS FOR MULTIDRUG RESISTANCE IN CANCERS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2015-01-08 | — | — | US | disclosed |
| US-8916589-B2 | Bradykinin B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| US-8916589-B2 | Bradykinin B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| US-8916589-B2 | Bradykinin B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| EP-2188254-B1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-03-21 | — | — | EP | disclosed |
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| WO-2009027450-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BDKRB1, BDKRB2, EDNRB | BDKRB1 1/4885F10 546/4885CNR1 72/4885 |
| US-20150011513-A1 | ALKYNE-, AZIDE- AND TRIAZOLE-CONTAINING FLAVONOIDS AS MODULATORS FOR MULTIDRUG RESISTANCE IN CANCERS | ABCG2, ABCB1, ABCC1 | BDKRB1 1728/4885F10 3037/4885CNR1 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.